Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 301 phase 2a trial for migraine prevention
NL-OMON57816Phase 2Withdrawn
- Sponsor
- Amgen
- Start
- Aug 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of zelminemab in migraine (3 arms), sponsored by Amgen. Primary endpoint: Change from baseline in mean monthly migraine days. Planned start Aug 2017; status: withdrawn.
02
Drugs
zelminemab
03
Conditions
migraine
Beyond the preview
Go deeper on NL-OMON57816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON57816.